15% TOPICAL RESORCINOL FOR HURLEY I-II HIDRADENITIS SUPPURATIVA.

Last updated: February 11, 2020
Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hidradenitis Suppurativa

Scalp Disorders

Acne Inversa

Treatment

N/A

Clinical Study ID

NCT04099212
FIS-RES-2018-01
  • Ages > 18
  • All Genders

Study Summary

Prospective, observational cross-sectional study to evaluate the response of patients with HS I-II to monotherapy treatment of topical resorcin 15%, taking into account its safety, impact on quality of life and subclinical evolution.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age > 18 years.

  • Diagnosed with HS Hurley I-II degree.

  • Patients that have at least 1 or more swollen up nodules and/or abscess.

  • Availability of affected region control ultrasound prior to resorcine treatmentbeginning.

Exclusion

Exclusion Criteria:

  • Age < 18 years.

  • Number of draining fistula above 20.

  • Patients in active treatment with immunomodulators.

  • Patients in active treatment with antibiotics.

Study Design

Total Participants: 40
Study Start date:
May 15, 2019
Estimated Completion Date:
August 30, 2020

Connect with a study center

  • Hospital Universitario Virgen Macarena

    Sevilla, 41009
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.